Articles

Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study

Department of Hematology, University Hospital of Salamanca (CAUSA/IBSAL) and Center for Biomedical Research in Network of Cancer (CIBERONC), Salamanca
Cancer Center Clínica Universidad de Navarra, CIMA; IDISNA; CIBERONC, Pamplona
Serve d’Hematologia Clínica, Institut Català D'Oncologia-L'Hospitalet. IDIBELL, Universitat de Barcelona, Barcelona
Hospital Morales Meseguer, IMIB-Pascual Parrilla, Universidad de Murcia, Murcia
Hospital Universitario Virgen del Rocío, Sevilla
Hospital Universitario Dr. Peset, Valencia
Hospital Universitario Central de Asturias, Oviedo
Institut Catalá D’Oncologia Girona, Girona
Institut Catalá D’Oncologia Badalona, Badalona
Hospital Universitario 12 de Octubre, Madrid
Complejo Hospitalario Universitario de Santiago, La Coruña
Hospital Universitario de Canarias, Tenerife
Hospital Donostia, San Sebastián
Hospital Universitario 12 de Octubre, Madrid
Department of Hematology, University Hospital of Salamanca (CAUSA/IBSAL) and Center for Biomedical Research in Network of Cancer (CIBERONC), Salamanca
Cancer Center Clínica Universidad de Navarra, CIMA; IDISNA; CIBERONC, Pamplona
Hospital Clinic i Provincial de Barcelona, IDIBAPS, Barcelona
Hospital Universitario 12 de Octubre, Madrid
Cancer Center Clínica Universidad de Navarra, CIMA; IDISNA; CIBERONC, Pamplona
Department of Hematology, University Hospital of Salamanca (CAUSA/IBSAL) and Center for Biomedical Research in Network of Cancer (CIBERONC), Salamanca
Haematologica Early view Feb 15, 2024 https://doi.org/10.3324/haematol.2023.284089